Abstract
2,4,6-Trichlorophenyl hydrazones 1-35 were synthesized and their in vitro antiglycation potential was evaluated. Compounds 14 (IC50 = 27.2 ± 0.00 μM), and 18 (IC50 = 55.7 ± 0.00 μM) showed an excellent activity against glycation of protein, better than the standard (rutin, IC50 = 70 ± 0.50 μM). This study thus identified a novel series of antiglycation agents. A structure-activity relationship has been studied, and all the compounds were characterized by spectroscopic techniques.
Keywords: 2,4,6-trichlorophenyl hydrazones, Schiff bases, Antiglycation, AGEPs, Glycation of protein., vitro antiglycation, spectroscopic, techniques, chemotherapeutic Schiff, antibacterial, antiproliferative
Medicinal Chemistry
Title: Synthesis of 2,4,6-Trichlorophenyl Hydrazones and their Inhibitory Potential Against Glycation of Protein
Volume: 7 Issue: 6
Author(s): Khalid Mohammed Khan, Zarbad Shah, Viqar Uddin Ahmad, Momin Khan, Muhammad Taha, Fazal Rahim, Humera Jahan, Shahnaz Perveen and M. Iqbal Choudhary
Affiliation:
Keywords: 2,4,6-trichlorophenyl hydrazones, Schiff bases, Antiglycation, AGEPs, Glycation of protein., vitro antiglycation, spectroscopic, techniques, chemotherapeutic Schiff, antibacterial, antiproliferative
Abstract: 2,4,6-Trichlorophenyl hydrazones 1-35 were synthesized and their in vitro antiglycation potential was evaluated. Compounds 14 (IC50 = 27.2 ± 0.00 μM), and 18 (IC50 = 55.7 ± 0.00 μM) showed an excellent activity against glycation of protein, better than the standard (rutin, IC50 = 70 ± 0.50 μM). This study thus identified a novel series of antiglycation agents. A structure-activity relationship has been studied, and all the compounds were characterized by spectroscopic techniques.
Export Options
About this article
Cite this article as:
Mohammed Khan Khalid, Shah Zarbad, Uddin Ahmad Viqar, Khan Momin, Taha Muhammad, Rahim Fazal, Jahan Humera, Perveen Shahnaz and Iqbal Choudhary M., Synthesis of 2,4,6-Trichlorophenyl Hydrazones and their Inhibitory Potential Against Glycation of Protein, Medicinal Chemistry 2011; 7 (6) . https://dx.doi.org/10.2174/157340611797928415
DOI https://dx.doi.org/10.2174/157340611797928415 |
Print ISSN 1573-4064 |
Publisher Name Bentham Science Publisher |
Online ISSN 1875-6638 |
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
Related Articles
-
Neurodegenerative Diseases and Flavonoids: Special Reference to Kaempferol
CNS & Neurological Disorders - Drug Targets Patents on Therapeutic and Cosmetic Applications of Bioactives of Crocus Sativus L. and their Production through Synthetic Biology Methods: A Review
Recent Patents on Biotechnology Mitochondria Sentencing About Cellular Life and Death: A Matter of Oxidative Stress
Current Pharmaceutical Design Mn (III) Tetrakis (4-Benzoic Acid) Porphyrin Protects Against Neuronal and Glial Oxidative Stress and Death After Spinal Cord Injury
CNS & Neurological Disorders - Drug Targets Non Enzymatic Glycated Proteins in the Blood and Cardiovascular Disease
Current Pharmaceutical Design Antioxidant Enzyme Mimics with Synergism
Mini-Reviews in Medicinal Chemistry Aldose Reductase Inhibitory Potential of Several Thiazolyl-thiazolidine- 2,4-Diones
Letters in Drug Design & Discovery Potential for Stem Cells Therapy in Alzheimer’s Disease: Do Neurotrophic Factors Play Critical Role?
Current Alzheimer Research The Heat Stress Response and Diabetes: More Room for Mitochondrial Implication
Current Pharmaceutical Design Emerging Use of Nanotechnology in the Treatment of Neurological Disorders
Current Pharmaceutical Design Editorial: The New Trial EMPAREG-OUTCOMES in Type 2 Diabetes: “and Death Shall Have no Dominion”?
Current Vascular Pharmacology Meet Our Regional Editor
CNS & Neurological Disorders - Drug Targets Getting to Know the Cast - Cellular Interactions and Signaling at the Neurovascular Unit
Current Pharmaceutical Design NAD(P)H Oxidase Activation: A Potential Target Mechanism for Diabetic Vascular Complications, Progressive β-Cell Dysfunction and Metabolic Syndrome
Current Drug Targets Hypoxia Inducible Factor-1 as a Target for Neurodegenerative Diseases
Current Medicinal Chemistry Clinical Potential of Minocycline for Schizophrenia
CNS & Neurological Disorders - Drug Targets Genomics, Proteomics and Metabolomics Approaches for Predicting Diabetic Nephropathy in Type 2 Diabetes Mellitus Patients
Current Diabetes Reviews Mesenchymal Stem Cells: New Approaches for the Treatment of Neurological Diseases
Current Stem Cell Research & Therapy Dicarbonyls Generation, Toxicities, Detoxifications and Potential Roles in Diabetes Complications
Current Protein & Peptide Science A<sub>3</sub> Adenosine Receptor: A Plausible Therapeutic Target for Cardio-Protection in Diabetes
Recent Patents on Cardiovascular Drug Discovery